{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT02815488: Phase 1/Phase 2 Interventional Terminated Chronic Obstructive Pulmonary Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00019422: Phase 2 Interventional Completed Brain and Central Nervous System Tumors
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LABRADIMIL, a synthetic bradykinin analog, is a potent bradykinin B2 receptor agonist. It increases vascular permeability by the activation of B2 receptors on the vascular endothelium. It also selectively increases uptake of molecular tracers in brain tumors.
Status:
Investigational
Source:
NCT03301896: Phase 1 Interventional Terminated Solid Tumors
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01125644: Phase 3 Interventional Unknown status Cryptococcosis or Aspergillosis Infections
(2010)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
SPK-843 is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B.
Status:
Investigational
Source:
NCT04588129: Phase 1 Interventional Completed Schizophrenia
(2021)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
INN:imocitrelvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:elzovantinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04454658: Phase 1 Interventional Active, not recruiting Myelofibrosis (MF)
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03645434: Phase 2 Interventional Completed Chronic Obstructive Pulmonary Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
